Skip to content

Precision, Paradromics, Blackrock

Neuralink and Synchron hog the headlines, but three second-tier companies achieved key breakthroughs in 2025–2026: Precision Neuroscience (Layer 7 FDA 510k 2025-03), Paradromics (Connexus FDA 2025-11), and Blackrock Neurotech (long-running BrainGate collaboration). Each fills a distinct niche, and together they define the commercial landscape of BCI.

1. Precision Neuroscience

Company Background

  • Founded in 2021 by Ben Rapoport (a former Neuralink co-founder)
  • Headquartered in New York
  • Funding ~$135 M (through 2024)

Product: Layer 7 Cortical Interface

  • Thin-film ECoG: thickness 1/5 of a human hair
  • 1024 electrodes
  • Inserted through a small skull incision (~1 cm)
  • Does not penetrate brain tissue (safer than Neuralink)

Positioning

"Safer than Neuralink, higher resolution than Stentrode"

Technical Advantages

  • Flexible thin film
  • Large-area coverage (multiple regions)
  • Easy to remove and replace
  • Capable of bidirectional operation (read + stimulate)

2. Precision Milestones

2023 First in Human

  • Transient implant (intraoperative use)
  • Removed post-op
  • Validated safety + signal quality

2024 Long-term Implant

  • First long-term implant patient
  • Months of recordings
  • Good signal quality

2025-03: FDA 510k Approval (K242618)

  • First 1024-channel BCI to clear FDA 510k
  • "Temporary implant" pathway (30 days)
  • Clinical diagnostic use

2025 Q3–Q4 Expansion

  • Expanded to long-term implants
  • 10+ patient cohort
  • Commercialization pathway established

3. Paradromics

Company Background

  • Founded in 2015 by Matt Angle
  • Headquartered in Austin
  • Funding ~$100 M

Product: Connexus Direct Data Interface

  • 1,000–10,000 electrodes
  • Each "module" carries 420 microwires
  • Multiple modules can be implanted concurrently
  • Wireless and wired versions

Technical Advantages

  • Highest channel density
  • Flexible distributed modules
  • Mature electronics design

4. Paradromics Milestones

2023 Animal Validation

  • Long-term recordings in pigs and sheep
  • Stability ≥ 6 months

2024 Human Preparation

  • IDE application
  • Manufacturing ramp-up

2025-11: FDA Breakthrough + IDE Approval

  • Official first human implant (expected late 2025)
  • Epilepsy monitoring as first indication
  • To expand into BCI intent decoding

2026 Projections

  • Small cohort (3–5 patients)
  • Full functional validation
  • Head-to-head competition with Neuralink on channel count

5. Blackrock Neurotech

Company Background

  • Founded in 2008 on top of Utah Array technology
  • Standard supplier for academic BCI research
  • Acquired by Tether / iCapital in 2023

Product: Utah Array Ecosystem

  • NeuroPort Array: Utah Array for research
  • MoveAgain: clinical version (in development)
  • Blackrock Cerebus: data acquisition system

Positioning

  • Long-standing partner of BrainGate
  • 20 years of implant experience
  • Covers the vast majority of academic BCI papers

6. Blackrock's MoveAgain

Design

  • Based on the Utah Array
  • Single array with 96 channels
  • Direct FDA 510k pathway

2021 FDA Breakthrough

  • Priority review pathway
  • Approval expected 2026–2027

Co-developed with Academia

  • BrainGate data from 2002 onward
  • Already accumulated experience across dozens of patients
  • Most robust safety dataset

7. Comparison Across the Three

Dimension Precision Paradromics Blackrock
Invasion Surface (thin film) Microwires Rigid needles
Channels 1024 1000+ (modular) 96 (typical)
2026 FDA 510k (temporary) IDE Breakthrough
Patient count 10+ 3–5 30+ (academic)
Positioning Clinical utility High density Research standard

The Complete 2026 BCI Landscape

Neuralink Synchron Precision Paradromics Blackrock
Channels 1024 16 1024 1000+ 96
Invasiveness Medium (threads) Low (vascular) Low (surface) Medium (microwires) High (needles)
FDA progress IDE IDE 510k 2025-03 IDE 2025-11 Breakthrough
Patient count 12+ 6+ 10+ 3–5 30+ (BrainGate)
Musk factor Very high None None None None

Niche differentiation: - Neuralink: aggressive full-stack - Synchron: safest, consumer-facing - Precision: high-resolution surface - Paradromics: high channel count, modular - Blackrock: academic gold standard

9. Capital Markets

2024–2025 Investment Boom

  • Neuralink: $1B+ cumulative
  • Synchron: $145 M
  • Precision: $135 M
  • Paradromics: $100 M
  • Blackrock: $200 M+ (Tether acquisition)

IPO Expectations

  • Synchron: 2026–2027
  • Precision: 2026–2027
  • Paradromics: 2027+
  • Blackrock: already acquired

Interest from Medical Device Giants

  • Medtronic (a DBS veteran): early BCI investments
  • Abbott (a later DBS entrant): possible Stentrode partnership
  • Boston Scientific: watching
  • An M&A wave expected in 2027

1. The Channel-Count Race

  • Neuralink, Paradromics, Precision all marching toward 10,000+ channels
  • But the decoding bottleneck is not channel count

2. Safety Improvements

  • Precision's surface approach, Synchron's endovascular approach
  • "Don't penetrate the brain" becoming the new paradigm

3. Full-stack vs Standard

  • Neuralink: full-stack
  • Blackrock: standard (used by BrainGate)
  • Both pathways coexist

4. AI Integration

  • LLM + BCI (Synchron × OpenAI)
  • All companies are catching up

11. International Competition

U.S. Dominance

  • 5 companies
  • FDA leadership

Rise of China

See China BCI Ecosystem.

  • Neuracle: NMPA approval 2026-03 (world's first commercialized)
  • StairMed, NeuraMatrix

Europe, Israel

  • Inbrain Neuroelectronics (Spain): graphene electrodes
  • Ceribell (Israel-U.S.): EEG diagnostics
  • HumanBrainsciences: to be watched

12. Logic Chain

  1. Neuralink + Synchron + Precision + Paradromics + Blackrock define the core 2026 BCI landscape.
  2. Precision Layer 7 got FDA 510k in 2025-03 — first 1024-channel approval.
  3. Paradromics Connexus obtained FDA IDE in 2025-11 — high channel count, modular.
  4. Blackrock is the academic gold standard; MoveAgain approval expected 2026–27.
  5. Niche differentiation: each company targets different indications/pathways.
  6. Capital + M&A: expect medical-device giants entering in 2027.
  7. China's Neuracle may become the first commercialized implantable BCI — reshaping the global regulatory landscape.

References

  • Rapoport et al. (2024). Minimally invasive cortical interface for human BCI. Neurosurgery.
  • FDA (2025). 510(k) Premarket Notification K242618 (Precision Layer 7).
  • Paradromics (2025). IDE submission announcement.
  • Musk et al. (2019). An integrated brain-machine interface platform with thousands of channels. JMIR Preprints.
  • Blackrock Neurotech (2024). NeuroPort Array Technical Specifications. blackrockneurotech.com

评论 #